TABLE 4.
Summary of Best-corrected Visual Acuity and Change From Baseline at Each Scheduled Follow-up Visit, Mean (±SD) [range]
| No. Participants Analyzed | Best-corrected Visual Acuity | Best-corrected Visual Acuity Change From Baseline [P, paired t test] | ||||
|---|---|---|---|---|---|---|
| Visit | SGDD | CPC | SGDD | CPC | SGDD | CPC |
| Baseline | 22 | 20 | 0.97 (±0.90) | 0.49 (±0.66) | — | — |
| [0–2.3] | [0–2.6] | |||||
| Month 1 | 22 | 15 | 0.94 (±0.86) | 0.68 (±0.72) | −0.03* (±0.18) | 0.12* (±0.20) |
| [0–2.3] | [0–2.6] | [−0.57 to 0.22] | [−0.10 to 0.60] | |||
| [0.49] | [0.035] | |||||
| Month 3 | 21 | 17 | 0.81 (±0.84) | 0.62 (±0.70) | −0.10 * (±0.27) | 0.08 * (±0.13) |
| [0–2.3] | [0–2.6] | [−0.88 to 0.22] | [−0.10 to 0.33] | |||
| [0.11] | [0.017] | |||||
| Month 6 | 19 | 19 | 0.84 (±0.77) | 0.56 (±0.74) | −0.03 (±0.28) | 0.05 (±0.30) |
| [0–2.3] | [0–2.6] | [−0.63 to 0.60] | [−0.49 to 0.70] | |||
| [0.64] | [0.49] | |||||
| Month 12 | 16 | 16 | 0.83 (±0.80) | 0.52 (±0.76) | −0.06 (±0.34) | 0.09 (±0.31) |
| [0–2.3] | [0–2.6] | [−0.88 to 0.57] | [−0.40 to 1.00] | |||
| [0.47] | [0.25] | |||||
| Year 2 | 6 | 9 | 0.68 (±0.88) | 0.81 (±1.03) | −0.28 * (±0.28) | 0.24 * (±0.46) |
| [0–2.3] | [0–3.0] | [−0.70 to 0.00] | [−0.30 to 1.33] | |||
| [0.057] | [0.16] | |||||
| Year 3 | 6 | 5 | 1.02 (1.05) | 0.96 (1.07) | −0.23 (±0.36) | 0.49 (±0.76) |
| [0–2.3] | [0–2.3] | [−0.78 to 0.00] | [−0.40 to 1.33] | |||
| [0.13] | [0.22] | |||||
*
For P<0.05.
**
For P<0.01.
***
For P<0.001 Obtained from 2-sample t test or Fisher Exact test for comparing between groups.
Due to missing data, the mean of the differences in BCVA between baseline and each follow-up visit may not equal the mean changes in BCVA.
P-value obtained from paired t test for within each group.
CPC indicates cyclophotocoagulation; best-corrected visual acuity; SGDD, second glaucoma drainage device.